The nature of self for T cells—a systems-level perspective

Granados, Diana Paola; Laumont, Céline M.; Thibault, Pierre; Perreault, Claude

doi:10.1016/j.coi.2014.10.012

Cited by 65 publications

(66 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three types of MS data acquisition methods are now available for the measurement of MHC-associated peptides: (1) DDA, (2) targeted data acquisition, and (3) data-independent acquisition (DIA) (60). DDA is a well-established and a widely used method for large-scale identification of MHC-associated peptides (61)(62)(63). In contrast, the targeted and the DIA approaches are still emerging, and both techniques are expected to offer unprecedented advantages in terms of reproducibility and quantitative accuracy for the measurement of MHC peptide ligands across multiple samples, as recently demonstrated in proteomics (64 -66).…”

mentioning

confidence: 99%

Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry*

Caron

Kowalewski

Koh

et al. 2015

Molecular & Cellular Proteomics

197

118

View full text Add to dashboard Cite

The myriad of peptides presented at the cell surface by class I and class II major histocompatibility complex (MHC) molecules are referred to as the immunopeptidome and are of great importance for basic and translational science. For basic science, the immunopeptidome is a critical component for understanding the immune system; for translational science, exact knowledge of the immunopeptidome can directly fuel and guide the development of next-generation vaccines and immunotherapies against autoimmunity, infectious diseases, and cancers. In this mini-review, we summarize established isolation techniques as well as emerging mass spectrometry-based platforms (i.e. SWATH-MS) to identify and quantify MHC-associated peptides. We also highlight selected biological applications and discuss important current technical limitations that need to be solved to accelerate the development of this field. Molecular & Cellular

show abstract

mentioning

confidence: 99%

Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry*

Caron

Kowalewski

Koh

et al. 2015

Molecular & Cellular Proteomics

197

118

View full text Add to dashboard Cite

show abstract

“…This can be considered in absolute terms or as a fraction of the number of MHC molecules available for presentation on a given cell type (Granados et al, 2014). Further, these values may be taken as a snapshot in time, or (perhaps more usefully) studied as the temporal landscape following cellular changes such as infection.…”

Section: Introductionmentioning

confidence: 99%

Quantifying epitope presentation using mass spectrometry

Croft

Purcell

Tscharke

2015

Molecular Immunology

View full text Add to dashboard Cite

“…This is because they generated more stable MHC-I-peptide complexes than their wild-type counterpart (Duan et al, 2014). Reasoning that cancer-specific MAPs might be exceedingly rare on hematopoietic cancer cells (because of their low mutation load), Claude Perreault (IRIC, Université de Montréal, Montréal, Canada) presented a proteogenomic approach to identify MAPs that are derived from germline polymorphisms, also called minor histocompatibility antigens (MiHAs) (Granados et al, 2015). Injection of allogenic MiHA-specific CD8T cells in the recipient will specifically kill hematopoietic cancer cells when (1) the donor and recipient are HLA-matched, (2) the target MiHA is present in the recipient but not the donor, and (3) the MiHA is specific to (or enriched on) hematopoietic cells.…”

Section: Identifying Ideal Targets For Cd8 T-cell-based Immunotherapymentioning

confidence: 99%

Meeting report – 9th IRIC International Symposium on Molecular Targets in Cancer Genomics

Laumont

Haberl

Ghugari

et al. 2015

Journal of Cell Science

View full text Add to dashboard Cite

Graduate students and postdoctoral fellows at the Institute for Research in Immunology and Cancer (IRIC) organized the 9th IRIC International Symposium on 14–15 May, 2015. The symposium was held at the IRIC, an ultra-modern research hub and training center located on the hilltop of the Université de Montréal campus in Montreal, Canada. This year's title was ‘Molecular Targets in Cancer Genomics', reflecting the common interest of the IRIC student community. Through four broadly themed sessions, organizers sought to highlight the new generation of anti-cancer strategies including targeted therapies directed against actionable cancer-specific mutations, and immunotherapies, which enhance immune responses against cancer. Both targeted and immunotherapies are tailored to cancer-specific features, and require precise knowledge of cancer cells, from their genome to their proteome. The focus of this symposium was on translating the molecular basis of cancer into a functional understanding of aberrant pathways, and to uncover novel targets to be exploited for cancer therapeutic strategies.

show abstract

The nature of self for T cells—a systems-level perspective

Cited by 65 publications

References 81 publications

Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry*

Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry*

Quantifying epitope presentation using mass spectrometry

Meeting report – 9th IRIC International Symposium on Molecular Targets in Cancer Genomics

Contact Info

Product

Resources

About